Malaria
Conditions
Keywords
Malaria, Falciparum, Direct membrane feeding, QT-NASBA, Asexual parasite, Asymptomatic carrier, Gametocytocidal, Gametocyte, Transmission blocking, Sexual stage, Primaquine, Dihydroartemisinin, Piperaquine, Gambia, Africa
Brief summary
In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers compared to the recommended dose of primaquine but with a decreased risk of haemolysis. Children (\> 1 year) and adults with normal Glucose-6-phosphate dehydrogenase enzyme levels but with asexual Plasmodium falciparum parasites on the day of screening will be invited to take part in this study.
Detailed description
To date, primaquine (PQ), an 8-aminoquinoline, is the only currently registered product able to clear P. falciparum mature gametocytes. However, its use has been and is still limited by its haematological toxicity (haemolytic anaemia), particularly but not exclusively in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd), in whom haemolysis can occur after a single PQ dose. Such an effect is dose-dependent. Considering that the current recommended dose was established several decades ago on a small number of experimentally challenged volunteers, it may be possible to obtain the same effect with a lower dose and hence decrease the risk of haemolysis. The proposed study is a four-arm, open label, randomized, controlled trial. G6PD-normal asymptomatic P. falciparum infected individuals identified through population screening will be randomized to receive either a complete course of dihydroartemisinin-piperaquine (DHA-PPQ) alone (control arm) or a complete course of DHA-PPQ plus a single dose of PQ at 3 differing dose strengths (intervention arms), i.e. 0.75mg/kg, 0.4mg base/kg and 0.2mg base/kg. The study is planned to enroll 1,200 individuals with an asymptomatic malaria infection during the rainy /transmission season (June - December) from villages around the MRC's field stations at Walikunda and Basse in The Gambia. Asymptomatic parasite carriers identified by qualitative (RDT) and quantitative (parasites counts \>20/µl by slide microscopy) methods during population screening exercises at the villages will be invited for a written informed consent and further screening to confirm eligibility, including tests for qualitative G6PD enzyme function (fluorescence spot test) and haemoglobin. If eligible, they will be assigned to one of four study arms using a block randomization scheme in a 1:1:1:1 ratio ensuring a balance in enrollment between the four groups. Enrolled participants will receive ACT treatment on days 0, 1 and 2. On day 2, participants allocated to the PQ arms will receive a dose of primaquine based on determined body weight. Each participant involvement consists of a maximum of 11 visits over a 42 day period after initiation of treatment. The primary end point is the prevalence of P. falciparum gametocyte carriers at day 7, as determined by QT-NASBA.
Interventions
DRUGDHA-PPQ
Participants will receive a 3 day course of DHA-PPQ
DRUGPQ (0.75)
Participants will receive a single dose of PQ at 0.75mg base/kg body weight
DRUGPQ (0.4)
Participants will receive a single dose of PQ at 0.4mg base/kg body weight
DRUGPQ (0.2)
Participants will receive a single dose of PQ at 0.2mg base/kg body weight
Sponsors
London School of Hygiene and Tropical Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
Age ≥1 year * Weight \>10 Kg * P. falciparum mono-infection, density of at least 20 parasites/μL * Axillary temperature \< 37.5ºC * Resident in the study area and willingness to reside for the duration of the study * Written informed consent (plus an assent in children \>12years of age)
Exclusion criteria
* G6PD Deficiency Haemoglobin \<8g/dl * Known allergy to any of the study medications * Known Pregnancy or breastfeeding * Clear/documented history of anti-malarial treatment 2 weeks before contact with study team * History of blood transfusion in the previous 3 months * Any chronic or acute conditions that might interfere with the study as judged by the research clinician * History of sickle cell anaemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of P. falciparum gametocyte carriers (QT-NASBA) | Day 7 | Proportion of study participants in each arm with P. falciparum gametocyte carriers as determined by quantitative nucleic acid sequence based amplification assay (QT-NASBA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of individuals infectious to mosquitoes (DMFA) | Day 7 | % of individuals whose day 7 blood samples when fed to mosquitoes by direct membrane feeding assay |
| Haemoglobin change | Day 0 and days 3, 7, 10, 14, 21, 28, 35 and 42 | Mean (±SD) difference in haemoglobin measured between baseline (day 0) and each follow up visit day by study arm |
| Prevalence of P.Falciparum gametocytes carriers | Days 3, 10, 14, 28 and 42 | Prevalence of P. falciparum gametocyte carriers on days 3, 10, 14, 28 and 42, as determined by QT-NASBA |
| Proportion of participants with recurrent infection (PCR adjusted and unadjusted) | Day 7 to Day 42 | % of participants previously negative for parasites with detectable parasite (by microscopy and PCR) in samples after day 7 |
| Occurrence of adverse events (AEs) and serious adverse events (SAEs) | Day 3 to Day 42 | Occurrence of adverse events (AEs) and serious adverse events (SAEs) during follow up |
| Prevalence of infection (asexual stages) | Day 3 | Proportion of participants carrying asexual forms of P. Falciparum on day 3 |
Countries
The Gambia
Outcome results
None listed